Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Connect Biopharma HoldingsCNTB -2.01%10 PS Ratio is 51.91 as of Aug. 18, 2026, which is 90% below its 10-year median of 500.00. GuruFocus rates CNTB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Connect Biopharma Holdings ranks worse than 79.48% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Connect Biopharma Holdings's share price is $2.44.
Connect Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.05. Hence, Connect Biopharma Holdings's PS Ratio for today is 51.91.
The historical rank and industry rank for Connect Biopharma Holdings's PS Ratio or its related term are showing as below:
CNTB'
s PS Ratio Range Over the Past 10 Years
Min: 42.98 Med: 500 Max: 3450
Current: 51.88
During the past 7 years, Connect Biopharma Holdings's highest PS Ratio was 3450.00. The lowest was 42.98. And the median was 500.00.
CNTB's PS Ratio is ranked worse than 79.48% of 931
companies
in the Biotechnology industry
Industry Median: 9.45
vs CNTB: 51.88
Connect Biopharma Holdings (NAS:CNTB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Connect Biopharma Holdings PS Ratio Related Terms
Connect Biopharma Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Connect Biopharma Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Connect Biopharma Holdings's Share Price of today is $2.44. Connect Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Connect Biopharma Holdings (CNTB) has a PS Ratio of 51.91 as of Aug. 18, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Connect Biopharma Holdings and its competitors. This is 90% below median its historical median of 500.00. Over the past decade, Connect Biopharma Holdings' PS Ratio has ranged from 42.98 to 3,450.00. According to the industry distribution chart, Connect Biopharma Holdings ranks #740 out of 931 companies in the Biotechnology industry, placing it in the top 79.5%.
Is Connect Biopharma Holdings' PS Ratio too high?
Connect Biopharma Holdings' current PS Ratio of 51.91 is 90% below median its 10-year median of 500.00. Over the past 10 years, this metric has ranged from a low of 42.98 to a high of 3,450.00. The Biotechnology industry median PS Ratio is 9.45. Connect Biopharma Holdings' value of 51.91 is 449.3% above this industry median. Based on the distribution chart, Connect Biopharma Holdings ranks #740 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' PS Ratio compare to CUE and HURA?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #740 out of 931 companies for PS Ratio. This places Connect Biopharma Holdings in the lower half of its industry. The industry median PS Ratio is 9.45. Connect Biopharma Holdings' value of 51.91 is 449.3% above this benchmark. Historically, Connect Biopharma Holdings' own PS Ratio has ranged from 42.98 to 3,450.00 over the past decade. While the company's 10-year median is 500.00 vs. the industry median of 9.45, Connect Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.45, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Connect Biopharma Holdings's current PS Ratio of 51.91 is 449.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current PS Ratio is 51.91, which is 90% below median its own 10-year median of 500.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current PS Ratio of 51.91. The current PS Ratio is 51.91, which is 90% below median its 10-year median of 500.00 and 449.3% above the Biotechnology industry median of 9.45. Connect Biopharma Holdings' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current PS Ratio is 51.91 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
10GF Score
Get the complete analysis for CNTB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
